The deal will allow Novavax to lift its “going concern” warning, which it first issued in 2023 due to having “substantial doubt” about its ability to survive.

Was this article helpful?
YesNo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window